2026 Lung Cancer Symposium

The Grand Event Center - Columbus, OH

1 Day Conference 

November 13th, 2026

4.25 AMA PRA Category 1 Credit™ Hours

Description

There is a persistent gap between rapidly evolving evidence in lung cancer management and its consistent application in clinical practice, particularly across academic and community settings. Major advances in early-stage disease—including perioperative immunotherapy and targeted therapy, the emergence of antibody-drug conjugates, and expanded use of comprehensive molecular testing (including circulating tumor DNA/liquid biopsies)—have outpaced routine adoption. Real-world data demonstrate variability in biomarker testing rates, staging practices, and use of guideline-concordant therapy, contributing to inconsistent care delivery and outcomes.

This activity brings together academic and community oncologists to align on current standards, improve integration of new therapies and diagnostics, and reduce variability in lung cancer care.

Objectives

1. Describe and apply perioperative management of NSCLC, including chemoimmunotherapy, radiation therapy, surgery, and tissue and blood-based biomarker testing

2. Interpret and integrate results of broad-based biomarker testing to guide treatment selection in patients with NSCLC

3. Select and implement appropriate first-line treatment strategies for driver mutation—positive NSCLC, including EGFR-targeted therapies

4. Integrate current evidence into multidisciplinary management approaches for SCLC across clinical settings

5. Identify and evaluate appropriate clinical trial options and incorporate clinical trial enrollment into treatment planning for patients with lung cancer

Need help with this conference?

Please contact the conference coordinator listed below:

Katie Jones
Email: katie.jones@osumc.edu